Andy Chen
Stock Analyst at Wolfe Research
(2.01)
# 2,701
Out of 4,670 analysts
26
Total ratings
38.89%
Success rate
-4.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Upgrades: Outperform | $697 | $605.92 | +15.03% | 2 | Nov 12, 2024 | |
| ALNY Alnylam Pharmaceuticals | Downgrades: Underperform | n/a | $244.89 | - | 2 | Nov 12, 2024 | |
| INCY Incyte | Initiates: Outperform | n/a | $71.72 | - | 1 | Oct 1, 2024 | |
| CLDX Celldex Therapeutics | Downgrades: Peer Perform | n/a | $27.02 | - | 3 | Sep 27, 2024 | |
| MLTX MoonLake Immunotherapeutics | Downgrades: Peer Perform | n/a | $54.32 | - | 2 | Aug 26, 2024 | |
| KYMR Kymera Therapeutics | Upgrades: Outperform | $65 | $44.98 | +44.51% | 2 | Aug 26, 2024 | |
| AKRO Akero Therapeutics | Initiates: Outperform | n/a | $32.73 | - | 1 | Jun 11, 2024 | |
| MDGL Madrigal Pharmaceuticals | Initiates: Outperform | n/a | $347.45 | - | 1 | Jun 11, 2024 | |
| VRDN Viridian Therapeutics | Initiates: Outperform | n/a | $20.20 | - | 1 | Jun 11, 2024 | |
| RAPT RAPT Therapeutics | Downgrades: Peer Perform | n/a | $1.08 | - | 3 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $34.01 | - | 1 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $47.88 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $12.53 | +35.67% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $26.87 | +104.69% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $14.30 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $450.97 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $73.15 | -42.58% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $60 | $2.62 | +2,190.08% | 1 | Aug 8, 2023 |
argenx SE
Nov 12, 2024
Upgrades: Outperform
Price Target: $697
Current: $605.92
Upside: +15.03%
Alnylam Pharmaceuticals
Nov 12, 2024
Downgrades: Underperform
Price Target: n/a
Current: $244.89
Upside: -
Incyte
Oct 1, 2024
Initiates: Outperform
Price Target: n/a
Current: $71.72
Upside: -
Celldex Therapeutics
Sep 27, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $27.02
Upside: -
MoonLake Immunotherapeutics
Aug 26, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $54.32
Upside: -
Kymera Therapeutics
Aug 26, 2024
Upgrades: Outperform
Price Target: $65
Current: $44.98
Upside: +44.51%
Akero Therapeutics
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $32.73
Upside: -
Madrigal Pharmaceuticals
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $347.45
Upside: -
Viridian Therapeutics
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $20.20
Upside: -
RAPT Therapeutics
May 14, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $1.08
Upside: -
Apr 10, 2024
Upgrades: Outperform
Price Target: n/a
Current: $34.01
Upside: -
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $47.88
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $17
Current: $12.53
Upside: +35.67%
Feb 15, 2024
Initiates: Outperform
Price Target: $55
Current: $26.87
Upside: +104.69%
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $14.30
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $450.97
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $42
Current: $73.15
Upside: -42.58%
Aug 8, 2023
Assumes: Buy
Price Target: $60
Current: $2.62
Upside: +2,190.08%